1. Home
  2. VRAX vs GNPX Comparison

VRAX vs GNPX Comparison

Compare VRAX & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • GNPX
  • Stock Information
  • Founded
  • VRAX 2013
  • GNPX 2009
  • Country
  • VRAX United Kingdom
  • GNPX United States
  • Employees
  • VRAX N/A
  • GNPX N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • GNPX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRAX Health Care
  • GNPX Health Care
  • Exchange
  • VRAX Nasdaq
  • GNPX Nasdaq
  • Market Cap
  • VRAX 5.9M
  • GNPX 6.2M
  • IPO Year
  • VRAX 2022
  • GNPX 2018
  • Fundamental
  • Price
  • VRAX $1.09
  • GNPX $0.27
  • Analyst Decision
  • VRAX Strong Buy
  • GNPX Strong Buy
  • Analyst Count
  • VRAX 1
  • GNPX 1
  • Target Price
  • VRAX $3.00
  • GNPX $10.00
  • AVG Volume (30 Days)
  • VRAX 300.7K
  • GNPX 7.3M
  • Earning Date
  • VRAX 02-05-2025
  • GNPX 05-13-2025
  • Dividend Yield
  • VRAX N/A
  • GNPX N/A
  • EPS Growth
  • VRAX N/A
  • GNPX N/A
  • EPS
  • VRAX N/A
  • GNPX N/A
  • Revenue
  • VRAX $84,872.00
  • GNPX N/A
  • Revenue This Year
  • VRAX $5,169.18
  • GNPX N/A
  • Revenue Next Year
  • VRAX $66.97
  • GNPX N/A
  • P/E Ratio
  • VRAX N/A
  • GNPX N/A
  • Revenue Growth
  • VRAX 7.03
  • GNPX N/A
  • 52 Week Low
  • VRAX $0.60
  • GNPX $0.22
  • 52 Week High
  • VRAX $9.00
  • GNPX $4.09
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 48.47
  • GNPX 44.92
  • Support Level
  • VRAX $0.91
  • GNPX $0.23
  • Resistance Level
  • VRAX $1.09
  • GNPX $0.44
  • Average True Range (ATR)
  • VRAX 0.11
  • GNPX 0.04
  • MACD
  • VRAX 0.03
  • GNPX 0.00
  • Stochastic Oscillator
  • VRAX 51.92
  • GNPX 26.65

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: